Advertisement
Advertisement
U.S. Markets open in 7 hrs
Advertisement
Advertisement
Advertisement
Advertisement

Advaxis, Inc. (ADXS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3679-0.0361 (-8.94%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4040
Open0.4019
Bid0.3674 x 1000
Ask0.3800 x 800
Day's Range0.3660 - 0.4040
52 Week Range0.2800 - 1.5700
Volume4,502,199
Avg. Volume6,800,760
Market Cap50.756M
Beta (5Y Monthly)2.30
PE Ratio (TTM)N/A
EPS (TTM)-0.3270
Earnings DateJan 20, 2022 - Jan 24, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
  • GlobeNewswire

    Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting

    Company releases video message highlighting the need for all proposals to pass in order to consummate the proposed Biosight transaction Advaxis urges stockholders to vote “FOR” all of the proposals at the special meeting in order to best position the company to build long term stockholder value MONMOUTH JUNCTION, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,

  • GlobeNewswire

    Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and Satisfy Initial Listing Requirements

    MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products, announced that it has received a letter from the Nasdaq Hearings Panel (the “Panel”) providing Advaxis an extension through December 20, 2021, to complete its business combination with Biosight, Ltd. (“Biosight”) and demonstrate compliance wit

  • GlobeNewswire

    Advaxis, Inc. Issues Letter to Stockholders

    Advaxis urges stockholders to carefully evaluate the potential outcomes of the vote on the proposed merger with Biosight and vote FOR all proposalsMONMOUTH JUNCTION, N.J., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today issued the following statement to stockholders: Dear Fellow Advaxis Stockholders: We have prepared this summary to highlight the starkly differ

Advertisement
Advertisement